RenMice-抗体開発プラットフォーム

RenMab®

RenMabマウスは、多様性、親和性、免疫原性が低い完全ヒトモノクローナル抗体の開発を目的として、ヒト抗体の重鎖および軽鎖可変領域を完全にin situで置換したマウスです。

このページで

  • 主な特徴
  • 検証データ
  • FAQs

ポスター

すべて表示

    主な特徴

    1. 完全なヒト重鎖およびκライトチェーンV(D)J座位のin situ置換
    Heavy Chain
    2. 完全ヒト抗体ライブラリの多様性
    Fully human antibody img Fully human antibody img 2
    3. 野生型マウスに匹敵する強力な免疫応答
    Immune response img Immune response img 2

    Frequently Asked Questions (FAQs) About RenMab

    1. What is RenMab®, and how does it generate fully human antibodies?

    RenMab® is Biocytogen’s fully human monoclonal antibody discovery platform within the RenMice® family. Powered by our proprietary Size-Unlimited and Precise Chromosome Engineering (SUPCE™) technology, RenMab® replaces mouse antibody genes with their human counterparts in situ. Natural heavy-light chain pairing and affinity maturation in vivo enable the discovery of diverse high-affinity fully human monoclonal antibodies with favorable developability.

    2. Why are fully human antibodies valuable for therapeutic development?

    Fully human antibodies can help reduce risk of immunogenicity associated with non-human sequences, including anti-drug antibody (ADA) formation. They also eliminate the need for downstream humanization, providing a direct route to therapeutic candidates while avoiding potential changes in binding or function during humanization.

    3. What is the genetic design strategy behind the RenMab® platform?

    Unlike random gene insertion approach, RenMab® uses precise in situ gene replacement to replace mouse heavy-chain V(D)J and kappa light-chain variable region loci with their human counterparts, creating a comprehensive human antibody variable-region repertoire. Our platform preserves native regulatory control to support B-cell development, natural antibody gene recombination and immune-driven antibody discovery.

    4. What other antibody discovery platforms and formats does Biocytogen offer?

    Beyond RenMab® for fully human monoclonal antibody discovery, Biocytogen offers: